证券代码：002349 证券简称：精华制药 精华制药集团股份有限公司投资者关系活动记录表 编号：0029 | --- | --- | --- | |-------------------------|-----------------------------|------------------------------------------------------| | | | | | 投资者关系活动 | √ 特定对象调研 | □ 分析师会议 | | 类别 | □ 媒体采访 | □ 业绩说明会 | | | □ 新闻发布会 | □ 路演活动 | | | □ 现场参观 | | | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称及 人员姓名 | | 上海方泉投资咨询有限公司 唐梦、冯永利 | | 时间 | 10：30-11：30 | | | 地点 | 公司接待室 | | | 上市公司接待人 | 董事会秘书 王剑锋 | | | 员姓名 | 证券事务部 金 燕 | | | 投资者关系活动 | 1 、 介绍下公司基本情况 | | | 主要内容介绍 | | 介绍了公司的历史沿革、主要产品、主要子公司情 ...

证券代码：002349 证券简称：精华制药 编号：0028 | --- | --- | --- | |----------------|-----------------------------------|--------------------------------------------------| | | | | | 投资者关系活动 | √ 特定对象调研 | □ 分析师会议 | | 类别 | □ 媒体采访 | □ 业绩说明会 | | | □ 新闻发布会 | □ 路演活动 | | | □ 现场参观 | | | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称及 | 上海石敢当投资管理有限公司 徐中哲 | | | 人员姓名 | 北京古槐资本投资有限公司 杜彤 | | | | 建信基金管理公司 王丽媛 | | | 时间 | 13：00-15 ： 00 | | | 地点 | 公司接待室 | | | 上市公司接待人 | 董事长 朱春林 | | | 员姓名 | 副总经理 杨小军 | | | | 董事会秘书 王剑锋 | | | | 1 、 介绍下公司基本情况 | | | 投资者关系活动 | | ...

证券代码：002349 证券简称：精华制药 精华制药集团股份有限公司投资者关系活动记录表 编号：0027 | --- | --- | --- | |-------------------------|-----------------------------|------------------------------------------------------| | | | | | 投资者关系活动 | √ 特定对象调研 | □ 分析师会议 | | 类别 | □ 媒体采访 | □ 业绩说明会 | | | □ 新闻发布会 | □ 路演活动 | | | □ 现场参观 | | | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称及 人员姓名 | 西南证券 何治力 | | | 时间 | 14：30-15 ： 30 | | | | | | | 地点 | 公司接待室 | | | | | | | 上市公司接待人 员姓名 | 证券事务代表 王剑锋 | | | 投资者关系活动 | 1、 介绍下公司基本情况 | | | 主要内容介绍 | | 介绍了公司的历史沿革、主要产品、主要子公司情况。 | | | 2 ...

证券代码：002349 证券简称：精华制药 精华制药集团股份有限公司投资者关系活动记录表 编号：0033 | --- | --- | --- | |-------------------------|-----------------------------|------------------------------------------------------| | | | | | 投资者关系活动 | √ 特定对象调研 | □ 分析师会议 | | 类别 | □ 媒体采访 | □ 业绩说明会 | | | □ 新闻发布会 | □ 路演活动 | | | □ 现场参观 | | | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称及 人员姓名 | 天风证券 潘海洋 | | | 时间 | 10：00-12 ： 00 | | | 地点 | 公司接待室 | | | 上市公司接待人 | 副总经理 杨小军 | | | 员姓名 | 董事会秘书 王剑锋 | | | 投资者关系活动 | 1 、 介绍下公司基本情况 | | | 主要内容介绍 | | 介绍了公司的历史沿革、主要产品、主要子公司情况。 | | | 2 ...

证券代码：002349 证券简称：精华制药 精华制药集团股份有限公司投资者关系活动记录表 编号：0032 | --- | --- | --- | |----------------|---------------------------------|-----------------------------------------------------| | | | | | 投资者关系活动 | √ 特定对象调研 | □ 分析师会议 | | 类别 | □ 媒体采访 | □ 业绩说明会 | | | □ 新闻发布会 | □ 路演活动 | | | □ 现场参观 | | | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称及 | 农银汇理基金管理有限公司 陈卫国 | | | 人员姓名 | 宝赞投资 杨伟 | | | 时间 | 15：30-17：00 | | | 地点 | 公司接待室 | | | 上市公司接待人 | 总 经 理 周云中 | | | 员姓名 | 董事会秘书 王剑锋 | | | | 证券事务部 金 燕 | | | 投资者关系活动 | 1 、 介绍下公司基本情况 | | | 主要内容介绍 | ...

证券代码：002349 证券简称：精华制药 精华制药集团股份有限公司投资者关系活动记录表 编号：0031 | --- | --- | --- | |-------------------------|-----------------------------|------------------------------------------------------| | | | | | 投资者关系活动 | √ 特定对象调研 | □ 分析师会议 | | 类别 | □ 媒体采访 | □ 业绩说明会 | | | □ 新闻发布会 | □ 路演活动 | | | □ 现场参观 | | | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称及 人员姓名 | | 南京证券股份有限公司 曹露 曹学松 祝辉明 | | 时间 | 13：30-15：00 | | | 地点 | 公司接待室 | | | 上市公司接待人 | 董事会秘书 王剑锋 | | | 员姓名 | 证券事务部 金 燕 | | | 投资者关系活动 | 1 、 介绍下公司基本情况 | | | 主要内容介绍 | | 介绍了公司的历史沿革、主要产品、主要子公 ...

证券代码：002349 证券简称：精华制药 精华制药集团股份有限公司投资者关系活动记录表 编号：0030 | --- | --- | --- | |-------------------------|-----------------------------|------------------------------------------------------| | | | | | 投资者关系活动 | √ 特定对象调研 | □ 分析师会议 | | 类别 | □ 媒体采访 | □ 业绩说明会 | | | □ 新闻发布会 | □ 路演活动 | | | □ 现场参观 | | | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称及 人员姓名 | 西京投资 陆翎 | | | 时间 | 10：30-11：30 | | | 地点 | 公司接待室 | | | 上市公司接待人 | 董事会秘书 王剑锋 | | | 员姓名 | 证券事务部 金 燕 | | | 投资者关系活动 | 1 、 介绍下公司基本情况 | | | 主要内容介绍 | | 介绍了公司的历史沿革、主要产品、主要子公司情况。 | | | 2 、 ...

证券代码：002349 证券简称：精华制药 精华制药集团股份有限公司投资者关系活动记录表 编号：0034 | --- | --- | --- | |-----------------------------|--------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------| | | | | | 投资者关系活动 | √ 特定对象调研 | □ 分析师会议 | | 类别 | □ 媒体采访 | □ 业绩说明会 | | | □ 新闻发布会 | □ 路演活动 | | | □ 现场参观 | | | | □ 其他 | （请文字说明其他活动内容） | | 参与单位名称及 人员姓名 | 信达澳银基金管理有限公司 睿扬投资 罗会 ...

Revenue and Profit - Revenue for Q3 2022 reached ¥383,482,150.04, an increase of 17.08% year-over-year, while total revenue for the year-to-date was ¥1,175,028,595.83, up 21.26% compared to the same period last year[7] - Net profit attributable to shareholders for Q3 2022 was ¥38,794,132.60, a significant increase of 71.48% year-over-year, with year-to-date net profit at ¥168,876,231.79, up 31.52%[7] - The net profit after deducting non-recurring gains and losses for Q3 2022 was ¥35,717,425.87, a remarkable increase of 457.91% year-over-year, while year-to-date figures showed an increase of 67.38% to ¥156,080,799.46[7] - Basic and diluted earnings per share for Q3 2022 were both ¥0.0476, reflecting a 71.22% increase compared to the same period last year[7] - Total operating revenue for the current period reached ¥1,175,028,595.83, an increase of 21.3% compared to ¥969,008,945.04 in the previous period[27] - Net profit for the current period was ¥189,378,012.57, representing a 55.8% increase from ¥121,591,358.11 in the previous period[30] - Earnings per share (EPS) for the current period was ¥0.2074, compared to ¥0.1577 in the previous period, reflecting a 31.5% increase[32] Assets and Liabilities - Total assets as of the end of Q3 2022 were ¥3,193,165,938.79, a slight decrease of 0.15% from the end of the previous year, while equity attributable to shareholders increased by 5.54% to ¥2,359,745,363.70[7] - The total liabilities are reported at ¥466,968,535.87, compared to ¥603,237,286.18 previously[23] - The company's total liabilities decreased to ¥492,014,940.07 from ¥628,539,798.06, indicating a reduction of approximately 21.7%[26] - Total equity attributable to shareholders increased to ¥2,359,745,363.70 from ¥2,235,838,542.50, marking a growth of 5.5%[26] Cash Flow - Cash flow from operating activities for the year-to-date was ¥247,371,958.46, representing an increase of 8.27% compared to the same period last year[7] - Cash inflow from operating activities totaled ¥1,210,617,750.13, an increase from ¥1,060,825,645.53 in the previous period[33] - The net cash flow from operating activities was $247,371,958.46, an increase from $228,477,820.16 in the previous period, reflecting a growth of approximately 4%[35] - Total cash inflow from investment activities reached $514,188,001.96, significantly higher than $241,445,648.28 in the prior period, marking an increase of about 113%[35] - The company reported a significant increase in cash received from investment recoveries, totaling $507,142,234.96, compared to $179,576,646.56 in the previous period, indicating a growth of approximately 182%[35] Expenses and Investments - The company reported a significant decrease in financial expenses, which were -¥14,093,562.17 for the year-to-date, a reduction of 1899.88% year-over-year due to increased deposit income and reduced bank loan interest payments[12] - Research and development expenses for the current period were ¥47,557,128.54, down from ¥53,347,000.10 in the previous period, a decrease of 10.8%[27] - The company has a long-term investment in equity amounting to ¥17,402,050.83, down from ¥19,093,016.10[23] Shareholder Information - The total number of common shareholders at the end of the reporting period is 152,377[16] - The largest shareholder, Nantong Industrial Holdings Group Co., Ltd., holds 34.39% of the shares, totaling 279,994,660 shares[16] Inventory and Receivables - Accounts receivable increased to ¥275,852,312.81 from ¥213,685,445.94, reflecting a growth of approximately 29%[20] - Inventory as of September 30, 2022, is valued at ¥332,331,582.47, up from ¥323,123,183.77[23]

Financial Performance - The company's operating revenue for the first half of 2022 was CNY 791,546,445.79, representing a 23.39% increase compared to CNY 641,476,445.23 in the same period last year[28]. - The net profit attributable to shareholders for the same period was CNY 130,082,099.19, up by 22.98% from CNY 105,777,610.05 year-on-year[28]. - The net profit after deducting non-recurring gains and losses was CNY 120,363,373.59, reflecting a 16.60% increase from CNY 103,228,338.93 in the previous year[28]. - The basic earnings per share increased to CNY 0.1598, a rise of 23.02% compared to CNY 0.1299 in the same period last year[28]. - The company achieved consolidated sales revenue of CNY 791.55 million, a year-on-year increase of 23.39%[48]. - The net profit attributable to the parent company was CNY 130 million, reflecting a year-on-year growth of 22.98%[48]. - Operating cash flow was CNY 142.55 million, down 22.55% compared to the previous year[54]. Assets and Liabilities - The total assets at the end of the reporting period were CNY 3,133,982,972.17, a decrease of 2.00% from CNY 3,198,096,241.82 at the end of the previous year[28]. - The net assets attributable to shareholders increased by 3.72% to CNY 2,319,053,070.76 from CNY 2,235,838,542.50 at the end of the previous year[28]. - Cash and cash equivalents decreased to ¥558,970,624.74, accounting for 17.84% of total assets, down from 20.37% last year[61]. - Accounts receivable increased to ¥280,132,631.50, representing 8.94% of total assets, up from 6.68% last year[61]. - Inventory increased to ¥345,390,156.01, accounting for 11.02% of total assets, compared to 10.10% last year[61]. Operational Highlights - The company operates in the pharmaceutical manufacturing industry, focusing on traditional Chinese medicine, chemical raw materials, and biopharmaceuticals[37]. - Key products include Wang's Baocuo Pills, which are used for various pediatric and adult digestive issues, and Jide Sheng Snake Medicine Tablets, known for their detoxifying and anti-inflammatory properties[38]. - The production of methyl hydrazine at Nantong Dongli increased by 80.97% year-on-year[50]. - The company launched new products in the chlorine and fluorine series, maintaining stable market share for certain products[50]. - The company applied for 12 patents during the reporting period, indicating a focus on innovation[54]. Quality Control and Certifications - The company has implemented strict quality control measures in production, adhering to GMP standards to ensure product safety and quality[42]. - The company received European COS certification for five products, and FDA on-site audits were passed for others, indicating strong quality control capabilities[47]. - The company has obtained GMP certification for its subsidiaries and some products have passed FDA and COS certifications, ensuring drug quality safety[124]. Environmental Management - The company reported a total COD emission of 16.7296 tons, well below the approved limit of 117.115 tons per year, indicating compliance with environmental standards[97]. - The ammonia nitrogen emissions were recorded at 0.3414 tons, significantly lower than the annual limit of 10.362 tons[97]. - The company has established a wastewater treatment facility with a daily capacity of 1000 tons, ensuring effective management of wastewater[100]. - The company has invested in air pollution control facilities, including a waste gas incineration system with capacities of 30,000 m³/h and 50,000 m³/h[100]. - The company has implemented a comprehensive waste management system, with no direct discharge of industrial wastewater and solid waste being properly collected and disposed of[103]. Risk Management - The management has highlighted potential risks related to raw material procurement, sales price declines, product quality, and environmental safety[5]. - The company faces risks related to industry policies, including increased regulatory scrutiny and potential impacts on future development due to government pricing adjustments[78]. - Raw material procurement risks are highlighted, particularly due to the volatility in prices and supply shortages of traditional Chinese medicine materials, which could adversely affect profitability[79]. - The company has invested significantly in drug research and development, but faces risks related to increased funding requirements and potential delays in drug registration processes[80]. Shareholder and Governance - The company plans not to distribute cash dividends or issue bonus shares for the half-year period, indicating a focus on reinvestment[92]. - The company has maintained a stable governance structure, with no changes in its board of directors or senior management during the reporting period[91]. - The total number of ordinary shareholders at the end of the reporting period is 167,182[178]. - The largest shareholder, Nantong Industrial Holding Group Co., Ltd., holds 34.39% of the shares, totaling 279,994,660 shares, with a decrease of 6,597,500 shares during the reporting period[181]. Employee and Community Engagement - The company emphasizes employee rights and satisfaction, focusing on health and safety, and talent development to ensure mutual growth[124]. - The company actively promotes traditional Chinese medicine culture, conducting numerous educational activities for youth in 2022[124].